Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
Inflammatory cytokines in the cerebrospinal fluid may contribute to the new muscle weakness,
fatigue and pain experienced by patients with post-polio syndrome. Intravenousimmunoglobulin
(IvIg) reduces this inflammation. The purpose of this study is to investigate the clinical
effect of IvIg in post-polio syndrome.